Mathers Edward T. - 24 Jun 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Reporting relationship: Director
Issuer ticker: RYTM
Reported as of: 24 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jun 2025, 16:45:07 UTC
Prior SEC filing: 23 Jun 2025
Next SEC filing: 27 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Zachary Bambach, attorney-in-fact

Key filing fact

Mathers Edward T. filed Form 4 for RHYTHM PHARMACEUTICALS, INC. (RYTM) on 26 Jun 2025.

Key facts

This page summarizes Mathers Edward T.'s Form 4 filing for RHYTHM PHARMACEUTICALS, INC. (RYTM).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 26 Jun 2025, 16:45.

Change

Previous filing in this sequence was filed on 23 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001328625 Primary reporting owner

Mathers Edward T

Relationship: Director
Address: 104 5TH AVE, 19TH FLOOR, NEW YORK
Signature: /s/ Zachary Bambach, attorney-in-fact
Signature date: 26 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RYTM transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +7,037
Change %
Price: $0.000000
Shares after: 7,037
Date: 24 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,037
Exercise price: $63.66
Footnotes: F1

RYTM transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +4,712
Change %
Price: $0.000000
Shares after: 4,712
Date: 24 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,712
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The options fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Footnote F3

The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.